Cancer News and Research

Latest Cancer News and Research

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

$New drug may help bone fractures heal more quickly after radiation exposure$

New drug may help bone fractures heal more quickly after radiation exposure

A drug currently under development by the University of Pittsburgh School of Medicine may help bone fractures heal more quickly after radiation exposure, according to a study by Pitt researchers. The study's results will be presented at 1 p.m. today during the American Society for Radiation Oncology (ASTRO) annual meeting in Chicago.

3 Nov 2009

IMC-RT does not benefit breast cancer patients

After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

ASTRO commends CMS for limiting payment reductions proposed for radiation oncology

ASTRO, the American Society for Radiation Oncology, today praised the Centers for Medicare and Medicaid Services (CMS) for limiting the payment reductions initially proposed for radiation oncology and spreading the remaining cuts over four years.

3 Nov 2009

EpiCept's request for continued listing on the Nasdaq Stock Market granted by Nasdaq Hearings Panel

EpiCept Corporation today announced that a Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market.

3 Nov 2009

Marriage for adult survivors of childhood cancer? Not likely, says new study

Adult survivors of childhood cancer are 20 to 25 percent more likely to never marry compared with siblings and the general population, Yale School of Medicine researchers report in a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

3 Nov 2009

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

New imaging technique for treatment of breast cancer

Researchers at Rush University Medical Center and Argonne National Laboratory are collaborating on a study to determine if an imaging technique used by NASA to inspect the space shuttle can be used to predict tissue damage often experienced by breast cancer patients undergoing radiation therapy. The study is examining the utility of three-dimensional thermal tomography in radiation oncology.

3 Nov 2009

Cambridge Research & Instrumentation launches inForm image analysis software

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the launch of inForm™, advanced image analysis software based on the company’s proprietary Machine Learning System (MLS). inForm solves biologists’ and cancer researchers’ challenging image analysis problems by combining fast and easy-to-use automated image processing with advanced learning features that enable the user to train the software to process images automatically.

3 Nov 2009

ART Advanced Research Technologies to secure $1.2M interim financing

ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced that earlier today it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act with KPMG Inc. in order to provide the company with the liquidity it requires to pursue its solicitation process.

2 Nov 2009

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.

2 Nov 2009

superDimension launches the iLogic electromagnetic navigation bronchoscopy tool

superDimension, Inc.®, a private company that develops minimally invasive interventional pulmonology devices, announced today the launch of the iLogic System for early lung cancer detection and diagnosis. The device is the second generation version of inReach(TM), superDimension's electromagnetic navigation bronchoscopy (ENB) minimally invasive tool.

2 Nov 2009

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.

2 Nov 2009

Phase Forward to support FDA's production rollout of the WebSDM tool

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a contract award to support the FDA’s production rollout of the company’s WebSDM™ Release 3.0 software, including the Empirica™ Study Clinical Trials Signal Detection system.

2 Nov 2009

ISB and Complete Genomics embark on the largest complete human genome disease association study

The Institute for Systems Biology (ISB) and Complete Genomics Inc. announced today that they are embarking on a large-scale human genome sequencing study of Huntington’s disease (HD). ISB has engaged Complete Genomics to sequence 100 genomes, the majority of which will be used to investigate this disease, with samples from affected individuals, family members, and matched controls to study modifiers of disease presentation and progression.

2 Nov 2009

Cooper Norcross Run the Bridge: More than 4,000 runners participate to support school for the disabled

More than a record 4,000 runners and walkers participated in yesterday’s Cooper Norcross Run the Bridge, presented by AmeriHealth New Jersey.

2 Nov 2009

John C. Lincoln Hospital first to use commercially-available LungPoint system

Broncus Technologies, Inc., a medical device company focused on developing minimally-invasive innovations for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that John C. Lincoln Hospital in Phoenix is the first hospital in the U.S. to use the commercially-available LungPoint system.

2 Nov 2009